文献速递临床免疫临床微生物

Lumipulse G TP-N 化学发光免疫分析作为梅毒筛查试验的评估

Evaluation of the Lumipulse G TP-N Chemiluminescent Immunoassay as a Syphilis Screening Test.
PubMed 文献 · J Clin Microbiol · 2017-09-06

该研究将 Lumipulse G TP-N 化学发光免疫分析与 Bioplex 2200 梅毒 IgG 多重流式免疫分析进行对比,在 4,134 例常规和 HIV 样本中评估性能与工作流程效率。两种自动化 assay 的总体符合率为 99.0%(95%CI 98.6%-99.2%;κ=0.89),Lumipulse G TP-N 获得首次及后续结果的时间更短。对 231 例筛查阳性样本进一步行 RPR 和 TP·PA 检测,Lumipulse G TP-N 与 TP·PA 的 PPA 为 98.9%、NPA 为 77.3%,且病历回顾提示其产生的假反应性结果更少。

要点

  • Lumipulse G TP-N 与 Bioplex 2200 在 4,134 例样本中总体符合率 99.0%(κ=0.89)。
  • Lumipulse G TP-N 获得首次及后续结果的时间更短,适合高通量筛查。
  • 与 TP·PA 相比,Lumipulse G TP-N 的 PPA 为 98.9%、NPA 为 77.3%。

核心结论

  • Lumipulse G TP-N 与 Bioplex 2200 性能特征相似,适合高通量梅毒筛查。

研究设计与样本

  • 研究对比 Lumipulse G TP-N 化学发光免疫分析与 Bioplex 2200 梅毒 IgG 多重流式免疫分析。
  • 共检测 4,134 例常规和 HIV 样本,筛查阳性样本(n=231)进一步行 RPR 和 TP·PA 检测。

主要发现

  • 两种自动化 assay 的总体符合率为 99.0%(95%CI 98.6%-99.2%;κ=0.89)。
  • Lumipulse G TP-N 获得首次及后续结果的时间更短。
  • RPR 反应性样本(n=82)结果与两种自动化 assay 完全一致,TP·PA assay 显示一些差异。
  • TP·PA 与 Lumipulse G TP-N 的 PPA 为 98.9%、NPA 为 77.3%;Bioplex 2200 的 PPA 为 100%、NPA 为 15.9%。
  • 病历回顾提示 Lumipulse G TP-N 产生的假反应性结果少 27 例,可减少额外确认性 RPR 和 TP·PA 检测需求。

关键数值与推荐

  • 两种自动化 assay 总体符合率 99.0%(95%CI 98.6%-99.2%;κ=0.89)。
  • TP·PA 与 Lumipulse G TP-N 的 PPA 为 98.9%、NPA 为 77.3%。
  • Bioplex 2200 与 TP·PA 的 PPA 为 100%、NPA 为 15.9%。

临床怎么用

  • Lumipulse G TP-N 可用于高通量临床实验室的梅毒筛查,并缩短结果报告时间。
  • 筛查阳性样本仍需按流程行 RPR 和 TP·PA 等确认试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A syphilis diagnosis is often aided by the detection of treponemal and nontreponemal antibodies. Automated treponemal antibody detection systems enable high-volume clinical laboratories to perform syphilis screening at a faster pace with lower labor costs. The Lumipulse G TP-N chemiluminescent immunoassay is an automated system that qualitatively detects IgG and IgM antibodies against Treponema pallidum antigens in human serum and plasma. To assess performance characteristics and workflow efficiency, the Lumipulse G TP-N assay was compared to the Bioplex 2200 Syphilis IgG multiplex flow immunoassay. Among the 4,134 routine and HIV samples tested by the two automated assays, the percentage of agreement was excellent at 99.0% (95% confidence interval [CI], 98.6% to 99.2%; κ, 0.89), with the Lumipulse G TP-N having a shorter time to first and subsequent results. All specimens with reactive syphilis screening results were further tested by rapid plasma reagin (RPR) and Treponema pallidum particle agglutination (TP·PA) testing (n = 231). The results from the RPR-reactive samples (n = 82) showed complete concordance with the two automated assays, while the TP·PA assay displayed some discrepancies. The positive percent agreement (PPA) and negative percent agreement (NPA) between the TP·PA test and the Lumipulse G TP-N test were 98.9% and 77.3%, respectively. The Bioplex 2200 Syphilis IgG immunoassay displayed a similar PPA (100%) but a substantially lower NPA (15.9%). Patient chart reviews of discrepant results suggested that the Lumipulse G TP-N assay produced 27 fewer falsely reactive results and can reduce the amount of additional confirmatory RPR and TP·PA testing needed. The analogous performance characteristics of the two automated systems indicate that the Lumipulse G TP-N assay is suitable for high-throughput syphilis screening.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Ortiz DA, Loeffelholz MJ. Evaluation of the Lumipulse G TP-N Chemiluminescent Immunoassay as a Syphilis Screening Test. J Clin Microbiol. 2017. PMID: 28878003. doi:10.1128/JCM.00966-17

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。